NVG-291, TAT-ISP (Human) peptide

• COA/MS/HPLC Report
• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

NVG-291 is a synthetic peptide analog of intracellular sigma peptide (ISP), developed to modulate the proteoglycan receptor PTPσ. This compound operates by inhibiting the interaction between chondroitin sulfate proteoglycans (CSPGs) and PTPσ, both of which suppress oligodendrocyte precursor cell (OPC) differentiation and remyelination. In investigations utilizing lysolecithin (LPC) and experimental autoimmune encephalomyelitis (EAE) models, ISP application was associated with increased OPC survival, proliferation, and maturation, contributing to improved axon remyelination.

TAT-ISP is a cell-penetrating variant of the intracellular sigma peptide, which incorporates the TAT protein transduction domain to support cellular internalization. This adaptation enables efficient entry into cells and engagement with intracellular PTPσ signaling mechanisms. In demyelination models, TAT-ISP delivery resulted in reduced gliosis and facilitated the differentiation of OPCs into mature myelinating oligodendrocytes, thereby promoting central nervous system repair through enhanced remyelination of affected axons.

• Lang BT, Cregg JM, DePaul MA, Tran AP, Xu K, Dyck SM, et al. Modulation of the proteoglycan receptor PTPσ promotes recovery after spinal cord injury. Nature. (2015) 518:404–8. doi: 10.1038/nature13974
• Kondiles BR, Rana S, Weiner D, Blesch A, St John J, Haag-Molkenteller C, Freund P, Guest J, Mikol DD, Harkema S, Trumbower RD, Fehlings MG, Weidner N, Hogge GS, Field-Fote EC, Baptista MAS, Curt A, Hsieh J, Jones L. Lessons Learned and Recommendations from a SCOPE Spinal Cord Injury Neurorestorative Clinical Trials Update. Neurotrauma Rep. 2025 Mar 5;6(1):210-231. doi: 10.1089/neur.2024.0163. PMID: 40309157; PMCID: PMC12040541.
• Allanach JR, Farrell JW 3rd, Mésidor M, Karimi-Abdolrezaee S. Current status of neuroprotective and neuroregenerative strategies in multiple sclerosis: A systematic review. Mult Scler. 2022 Jan;28(1):29-48. doi: 10.1177/13524585211008760. Epub 2021 Apr 19. PMID: 33870797; PMCID: PMC8688986.

Trifluoroacetic acid (TFA) is a common counterion from the purification process using High-Performance Liquid Chromatography (HPLC). The presence of TFA can affect the peptide's net weight, appearance, and solubility.

Impact on Net Weight: The TFA salt contributes to the total mass of the product. In most cases, the peptide content constitutes >80% of the total weight, with TFA accounting for the remainder.

Solubility: TFA salts generally enhance the solubility of peptides in aqueous solutions.

In Biological Assays: For most standard in vitro assays, the residual TFA levels do not cause interference. However, for highly sensitive cellular or biochemical studies, please be aware of its presence.